NDA filing expected in second half of 2016
Cambridge, UK – 21st March 2016: Acacia Pharma Group plc (“Acacia Pharma”), the supportive care company developing products for US and international markets, announces the initiation of its second pivotal Phase 3 treatment study, investigating BAREMSIS™ (amisulpride injection, formerly APD421) in surgical patients who develop post-operative nausea & vomiting (PONV), despite having received antiemetic prophylaxis before surgery.
LEXINGTON, Mass., March 2, 2016 /PRNewswire/ -- scPharmaceuticals, Inc., announced today that the pivotal trial for its ceftriaxone program met the targeted end-points. The primary end-point for the study is non-inferior antimicrobial coverage when compared to the same dose given by intravenous infusion. Antimicrobial coverage refers to time over the Minimum Inhibitory Concentration (MIC), a generally accepted measure of the adequacy of plasma levels of an antibiotic for treatment of infections due to susceptible bacteria.
DySIS Colposcope to be incorporated into national cervical screening programme
EDINBURGH, Scotland--(BUSINESS WIRE)--DySIS Medical Ltd. (DySIS) today announces that it has signed a multi-million pound contract with medical technology distributor, ITEM Medical Technologies as part of the national cervical screening programme in Turkey. No financial details have been disclosed.
|Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste|